The fMCAO model is an ideal method for highlightingthe side effects of the drug and comparing the safety profiles oftPA-DPN and free tPA, as it exacerbates stroke injury caused by tPAadministration, enabling a more accurate evaluation of the effectsof delayed tPA treatment. This evidence concerns the gene PLAT and Stroke.